Journal ArticleOPEN ACCESS

Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer

Geburtshilfe und Frauenheilkunde (2016) 76(2) 147-149
DOI: 10.1055/s-0035-1568169
14Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The AGO Kommission Ovar already published a statement in 2013, warning about the uncritical use of hyperthermic intraperitoneal chemotherapy (HIPEC) outside controlled studies. This statement has now been updated after the most recent literature was reviewed by AGO Kommission Ovar, the AGO Study Group, NOGGO, AGO Austria and AGO Switzerland. The authors conclude that HIPEC remains experimental. Its use is not recommended and should be rejected outside of prospective controlled trials.

Author supplied keywords

Cite

CITATION STYLE

APA

Harter, P., Du Bois, A., Mahner, S., Pfisterer, J., Ortmann, O., Marth, C., … Sehouli, J. (2016). Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer. Geburtshilfe Und Frauenheilkunde, 76(2), 147–149. https://doi.org/10.1055/s-0035-1568169

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free